BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 27521848)

  • 1. Chloroquine inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation.
    Yang M; Huang L; Li X; Kuang E
    Antiviral Res; 2016 Sep; 133():223-33. PubMed ID: 27521848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
    Huang L; Yang M; Yuan Y; Li X; Kuang E
    Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of the Human Kinome Identifies MSK1/2-CREB1 as an Essential Pathway Mediating Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication during Primary Infection.
    Cheng F; Sawant TV; Lan K; Lu C; Jung JU; Gao SJ
    J Virol; 2015 Sep; 89(18):9262-80. PubMed ID: 26109721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
    Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
    J Virol; 2017 May; 91(10):. PubMed ID: 28275189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib Inhibits the Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus through Down-Regulation of RTA Expression by Inhibiting the Activation of p38 MAPK.
    Chen J; Jiang L; Lan K; Chen X
    Viruses; 2015 May; 7(5):2268-87. PubMed ID: 25951487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an ORF45-Derived Peptide To Inhibit the Sustained RSK Activation and Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.
    Li X; Huang L; Xiao Y; Yao X; Long X; Zhu F; Kuang E
    J Virol; 2019 May; 93(10):. PubMed ID: 30842327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase.
    Cheng F; He M; Jung JU; Lu C; Gao SJ
    J Virol; 2016 Jul; 90(14):6515-6525. PubMed ID: 27147746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy.
    Andrei G; Snoeck R
    Curr Opin Infect Dis; 2015 Dec; 28(6):611-24. PubMed ID: 26524334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNase Activity of Kaposi's Sarcoma-Associated Herpesvirus SOX Protein Serves an Important Role in Viral Genome Processing during Lytic Replication.
    Uppal T; Meyer D; Agarwal A; Verma SC
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.
    Xie J; Ajibade AO; Ye F; Kuhne K; Gao SJ
    Virology; 2008 Feb; 371(1):139-54. PubMed ID: 17964626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
    Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
    PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.
    Pan H; Xie J; Ye F; Gao SJ
    J Virol; 2006 Jun; 80(11):5371-82. PubMed ID: 16699017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptome analysis of Kaposi's sarcoma-associated herpesvirus during de novo primary infection of human B and endothelial cells.
    Purushothaman P; Thakker S; Verma SC
    J Virol; 2015 Mar; 89(6):3093-111. PubMed ID: 25552714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.
    Xu D; Coleman T; Zhang J; Fagot A; Kotalik C; Zhao L; Trivedi P; Jones C; Zhang L
    J Virol; 2007 Jun; 81(11):6068-78. PubMed ID: 17376914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hesperetin inhibits KSHV reactivation and is reversed by HIF1α overexpression.
    Long WY; Zhao GH; Wu Y
    J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34747688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
    Sharma-Walia N; Krishnan HH; Naranatt PP; Zeng L; Smith MS; Chandran B
    J Virol; 2005 Aug; 79(16):10308-29. PubMed ID: 16051824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KSHV targeted therapy: an update on inhibitors of viral lytic replication.
    Coen N; Duraffour S; Snoeck R; Andrei G
    Viruses; 2014 Nov; 6(11):4731-59. PubMed ID: 25421895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
    Jiang Y; Xu D; Zhao Y; Zhang L
    PLoS One; 2008 Feb; 3(2):e1569. PubMed ID: 18253508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug.
    Nichols LA; Adang LA; Kedes DH
    PLoS One; 2011 Jan; 6(1):e14535. PubMed ID: 21264294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.
    Gorres KL; Daigle D; Mohanram S; Miller G
    J Virol; 2014 Jul; 88(14):8028-44. PubMed ID: 24807711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.